Differential Effects of Tat Proteins Derived from HIV-1 Subtypes B and Recombinant CRF02_AG on Human Brain Microvascular Endothelial Cells: Implications for Blood-brain Barrier Dysfunction

Overview

Journal J Cereb Blood Flow Metab

Publisher Sage Publications

Specialties Cardiology & Vascular Diseases
Endocrinology
Neurology

Date 2014 Mar 27

PMID 24667918

Citations 28

Authors

Shawna M Woollard

Biju Bhargavan

Fang Yu

Georgette D Kanmogne

Affiliations

Soon will be listed here.

Abstract

HIV-1 genetic differences influence viral replication and progression to AIDS. HIV-1 circulating recombinant form (CRF)02_AG is the predominant viral subtype infecting humans in West and Central Africa, but its effects on HIV neuropathogenesis are not known. In the present study, we investigated the effects of Tat proteins from HIV-1 subtype B (Tat.B) and HIV-1 CRF02_AG (Tat.AG) on primary human brain microvascular endothelial cells (HBMEC), the major component of the blood-brain barrier (BBB). Using Affymetrix GeneChip Human Gene 1.0.ST arrays, we showed that Tat.AG had minimal effects while Tat.B induced transcriptional upregulation of 90 genes in HBMEC, including proinflammatory chemokines, complement components C3, C7, and complement factor B, matrix metalloproteinases (MMP)-3, MMP-10, and MMP-12. These results were confirmed by real-time PCR. Compared with Tat.AG, Tat.B significantly increased MMP-3, MMP-10, and MMP-12 activities in HBMEC, and the MMPs tissue inhibitor of metalloproteinase-2 blocked Tat-induced increase in MMPs activity. Western blot analyses also showed that Tat increased the expression of C3 and its cleaved fragment C3b in HBMEC. These data suggest that genetic differences between HIV-1 subtypes B and CRF02_AG influence the effects of Tat proteins from these two clades on HBMEC, including molecular and cellular functions, and canonical pathways, which would affect BBB dysfunction and viral neuropathogenesis.

Citing Articles

C3a Mediates Endothelial Barrier Disruption in Brain-Derived, but Not Retinal, Human Endothelial Cells.

Wolf H, Guempelein L, Schikora J, Pauly D Int J Mol Sci. 2024; 25(20).

PMID: 39457022 PMC: 11508547. DOI: 10.3390/ijms252011240.

HIV Infection, Antiretroviral Drugs, and the Vascular Endothelium.

Kanmogne G Cells. 2024; 13(8.

PMID: 38667287 PMC: 11048826. DOI: 10.3390/cells13080672.

Immunohistochemical Expression of the SERPINA3 Protein in Uterine Fibroids.

de Mezer M, Markowska A, Markowska J, Krzyzaniak M, Grabarek B, Pokusa F Curr Pharm Biotechnol. 2024; 25(13):1758-1765.

PMID: 38204235 DOI: 10.2174/0113892010264673231111082438.

Disruption of blood-brain barrier: effects of HIV Tat on brain microvascular endothelial cells and tight junction proteins.

Sun Y, Cai M, Liang Y, Zhang Y J Neurovirol. 2023; 29(6):658-668.

PMID: 37899420 DOI: 10.1007/s13365-023-01179-3.

SERPINA3: Stimulator or Inhibitor of Pathological Changes.

de Mezer M, Rogalinski J, Przewozny S, Chojnicki M, Niepolski L, Sobieska M Biomedicines. 2023; 11(1).

PMID: 36672665 PMC: 9856089. DOI: 10.3390/biomedicines11010156.

References

Westendorp M, Frank R, Ochsenbauer C, Stricker K, Dhein J, Walczak H . Sensitization of T cells to CD95-mediated apoptosis by HIV-1 Tat and gp120. Nature. 1995; 375(6531):497-500. DOI: 10.1038/375497a0. View

Antinori A, Arendt G, Becker J, Brew B, Byrd D, Cherner M . Updated research nosology for HIV-associated neurocognitive disorders. Neurology. 2007; 69(18):1789-99. PMC: 4472366. DOI: 10.1212/01.WNL.0000287431.88658.8b. View

Jongen P, Doesburg W, Lemmens W, Hommes O, Lamers K . Cerebrospinal fluid C3 and C4 indexes in immunological disorders of the central nervous system. Acta Neurol Scand. 2000; 101(2):116-21. DOI: 10.1034/j.1600-0404.2000.101002116.x. View

Boyer V, Desgranges C, Trabaud M, FISCHER E, Kazatchkine M . Complement mediates human immunodeficiency virus type 1 infection of a human T cell line in a CD4- and antibody-independent fashion. J Exp Med. 1991; 173(5):1151-8. PMC: 2118846. DOI: 10.1084/jem.173.5.1151. View

Speth C, Stockl G, Mohsenipour I, Wurzner R, Stoiber H, Lass-Florl C . Human immunodeficiency virus type 1 induces expression of complement factors in human astrocytes. J Virol. 2001; 75(6):2604-15. PMC: 115884. DOI: 10.1128/JVI.75.6.2604-2516.2001. View

Hummel V, Kallmann B, Wagner S, Fuller T, Bayas A, Tonn J . Production of MMPs in human cerebral endothelial cells and their role in shedding adhesion molecules. J Neuropathol Exp Neurol. 2001; 60(4):320-7. DOI: 10.1093/jnen/60.4.320. View

Roe K, Kumar M, Lum S, Orillo B, Nerurkar V, Verma S . West Nile virus-induced disruption of the blood-brain barrier in mice is characterized by the degradation of the junctional complex proteins and increase in multiple matrix metalloproteinases. J Gen Virol. 2012; 93(Pt 6):1193-1203. PMC: 3755517. DOI: 10.1099/vir.0.040899-0. View

Davis G, Senger D . Endothelial extracellular matrix: biosynthesis, remodeling, and functions during vascular morphogenesis and neovessel stabilization. Circ Res. 2005; 97(11):1093-107. DOI: 10.1161/01.RES.0000191547.64391.e3. View

Montavon C, Toure-Kane C, Liegeois F, Mpoudi E, Bourgeois A, Vergne L . Most env and gag subtype A HIV-1 viruses circulating in West and West Central Africa are similar to the prototype AG recombinant virus IBNG. J Acquir Immune Defic Syndr. 2000; 23(5):363-74. DOI: 10.1097/00126334-200004150-00001. View

10.

Ranga U, Shankarappa R, Siddappa N, Ramakrishna L, Nagendran R, Mahalingam M . Tat protein of human immunodeficiency virus type 1 subtype C strains is a defective chemokine. J Virol. 2004; 78(5):2586-90. PMC: 369202. DOI: 10.1128/jvi.78.5.2586-2590.2004. View

11.

Eugenin E, King J, Nath A, Calderon T, Zukin R, Bennett M . HIV-tat induces formation of an LRP-PSD-95- NMDAR-nNOS complex that promotes apoptosis in neurons and astrocytes. Proc Natl Acad Sci U S A. 2007; 104(9):3438-43. PMC: 1805607. DOI: 10.1073/pnas.0611699104. View

12.

Vasan A, Renjifo B, Hertzmark E, Chaplin B, Msamanga G, Essex M . Different rates of disease progression of HIV type 1 infection in Tanzania based on infecting subtype. Clin Infect Dis. 2006; 42(6):843-52. DOI: 10.1086/499952. View

13.

Persidsky Y, Ramirez S, Haorah J, Kanmogne G . Blood-brain barrier: structural components and function under physiologic and pathologic conditions. J Neuroimmune Pharmacol. 2007; 1(3):223-36. DOI: 10.1007/s11481-006-9025-3. View

14.

Silvers J, Aksenova M, Aksenov M, Mactutus C, Booze R . Neurotoxicity of HIV-1 Tat protein: involvement of D1 dopamine receptor. Neurotoxicology. 2007; 28(6):1184-90. PMC: 2957183. DOI: 10.1016/j.neuro.2007.07.005. View

15.

Power C, Henry S, Del Bigio M, Larsen P, Corbett D, Imai Y . Intracerebral hemorrhage induces macrophage activation and matrix metalloproteinases. Ann Neurol. 2003; 53(6):731-42. DOI: 10.1002/ana.10553. View

16.

Xu R, Feng X, Xie X, Zhang J, Wu D, Xu L . HIV-1 Tat protein increases the permeability of brain endothelial cells by both inhibiting occludin expression and cleaving occludin via matrix metalloproteinase-9. Brain Res. 2011; 1436:13-9. DOI: 10.1016/j.brainres.2011.11.052. View

17.

Carr J, Salminen M, Albert J, Sanders-Buell E, Gotte D, Birx D . Full genome sequences of human immunodeficiency virus type 1 subtypes G and A/G intersubtype recombinants. Virology. 1998; 247(1):22-31. DOI: 10.1006/viro.1998.9211. View

18.

Zhou B, Liu Y, Kim B, Xiao Y, He J . Astrocyte activation and dysfunction and neuron death by HIV-1 Tat expression in astrocytes. Mol Cell Neurosci. 2004; 27(3):296-305. DOI: 10.1016/j.mcn.2004.07.003. View

19.

Hawkins B, Davis T . The blood-brain barrier/neurovascular unit in health and disease. Pharmacol Rev. 2005; 57(2):173-85. DOI: 10.1124/pr.57.2.4. View

20.

Hudson L, Liu J, Nath A, Jones M, Raghavan R, Narayan O . Detection of the human immunodeficiency virus regulatory protein tat in CNS tissues. J Neurovirol. 2000; 6(2):145-55. DOI: 10.3109/13550280009013158. View